Literature DB >> 25835401

Nivolumab approved for lung cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25835401     DOI： 10.1158/2159-8290.CD-NB2015-042

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  8 in total

Review 1.  Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Authors:  Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli
Journal:  Eur J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 4.191

2.  Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1.

Authors:  Yan Li; Lina Lu; Shiguang Qian; John J Fung; Feng Lin
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

Review 3.  The role of radiology in the evaluation of the immunotherapy efficacy.

Authors:  Marco Calandri; Federica Solitro; Valeria Angelino; Federica Moretti; Andrea Veltri
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Authors:  Sandra Huicochea Castellanos; Andrew Pagano; Andrew J Plodkowski; Jeffrey Girshman; Matthew D Hellmann; Hira Rizvi; Jessica Flynn; Junting Zheng; Marinela Capanu; Darragh F Halpenny; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2021-09-04       Impact factor: 5.705

5.  Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.

Authors:  Yu Chen; Gang Chen; Jin Li; Ying-Ying Huang; Yi Li; Jing Lin; Li-Zhu Chen; Jian-Ping Lu; Yu-Qi Wang; Chang-Xi Wang; Leong Kin Pan; Xue-Feng Xia; Xin Yi; Chuan-Ben Chen; Xiong-Wei Zheng; Zeng-Qing Guo; Jian-Ji Pan
Journal:  JAMA Netw Open       Date:  2019-09-04

6.  The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Authors:  Mehrdad Talebian Yazdi; Sander van Riet; Annemarie van Schadewijk; Marta Fiocco; Thorbald van Hall; Christian Taube; Pieter S Hiemstra; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-01-19

Review 7.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

8.  Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

Authors:  Jacob J Adashek; Shumei Kato; Roberto Ferrara; Giuseppe Lo Russo; Razelle Kurzrock
Journal:  Oncologist       Date:  2019-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.